Medtronic Cardiac Ablation Solutions
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Medtronic Cardiac Ablation Solutions sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Medtronic Cardiac Ablation Solutions: 20 sponsored US clinical trials, 6 recruiting.
Medtronic Cardiac Ablation Solutions sponsors 20 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 11 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atrial Fibrillation, with 5 trials.
Top-decile sponsor footprint
Medtronic Cardiac Ablation Solutions ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
NCT07298473
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
NCT07308847
SPHERE Per-AF Post-Approval Study
NCT06858306
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
NCT06703489
PULSED AF Post-Approval Study
NCT06578104
STOP AF First Post-Approval Study
NCT05227053
STOP Persistent AF PAS
NCT05005949
DIAMOND AF Post-Approval Study
NCT05230524
Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System
NCT05120193
Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
NCT04198701
ArcticLine Feasibility Study
NCT03604263
DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation
NCT03643224
DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation
NCT03334630
STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation
NCT03118518
STOP Persistent AF
NCT03012841
Cryo Global Registry
NCT02752737
Evaluation of the Phased Radio Frequency Ablation System
NCT01693120
Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)
NCT01456949
Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia
NCT01426425
Study for Atrial Fibrillation Reduction (SAFARI)
NCT00267137
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Where Medtronic Cardiac Ablation Solutions enrollment is open (later-stage tilt)
6 recruiting of 20 indexed (30% open); 11 completed (55%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Atrial Fibrillation (5 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Medtronic Cardiac Ablation Solutions: open-pipeline peers nationwide
Peers matched on 20 registered trials and 30% open enrollment, not the therapeutic-area sidebar.
Medtronic Cardiac Ablation Solutions sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 30% open enrollment (± trial volume)
- Adverum Biotechnologies · 30% recruiting · 10 trials
- Centre hospitalier de l'Université de Montréal (CHUM) · 30% recruiting · 10 trials
- Child Trends · 30% recruiting · 10 trials
- Jacques E. Chelly · 30% recruiting · 10 trials
Related
What to do with this Medtronic Cardiac Ablation Solutions page
20 registered trials is a research-attention snapshot, not an endorsement of Medtronic Cardiac Ablation Solutions or any single study.
- 6 of Medtronic Cardiac Ablation Solutions's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atrial Fibrillation is the condition Medtronic Cardiac Ablation Solutions studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atrial Fibrillation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Medtronic Cardiac Ablation Solutions pipeline card: 20 registered trials from official public datasets.Report a data error.